Alira Health and Sancare Join Forces to Drive Healthcare Innovation in France

Framingham, Mass. – January 11, 2024 – Alira Health, a global advisory and clinical research firm, and Sancare, an award-winning firm whose mission is to harness the potential of hospital data through artificial intelligence (AI), announced the launch of their partnership today. The companies are joining forces to unlock Realli™, a game-changing source of deep hospital Electronic Medical Record (EMR) data linked with claims from an expanding federated network of French hospitals, augmented with AI. With these new capabilities and the combination of Alira Health’s expertise and extensive industry knowledge and Sancare’s technology and expertise in hospital data systems, the partnership will accelerate innovation by optimizing development and broadening access to healthcare solutions for the benefit of patients and care providers.

News
Published on:
January 11, 2024
Our collaboration creates a central source for study design, data analysis, and communication of actionable insights that address needs for clinical research and market access in France and beyond."
Jean-François Ricci Chief Access Officer, Alira Health

“Through the partnership between Alira Health and Sancare, we combine our strengths to create a comprehensive end-to-end service offering that enables data access, analytics, and evidence generation strategy, providing impactful real-world solutions with purpose for patients,” said Jean-François Ricci, Chief Access Officer at Alira Health. “Our collaboration creates a central source for study design, data analysis, and communication of actionable insights that address needs for clinical research and market access in France and beyond.”

“Our partnership brings new capabilities for healthcare and life sciences organizations, especially for Real-World Evidence (RWE) studies and for data owners,” said Thomas Duval, CEO of Sancare. “By uniting Alira Health’s strengths as a Global Advisory and Contract Research Organization (CRO) with Sancare’s technology, data, and network, we enable important new evidence resources for companies developing solutions for patients.”

In joining forces to link EMR and claims data from a solid and growing hospital network, the partnership helps to overcome the significant limitations of the traditional approach to current claims data and prospective cohorts. By enabling access to large volumes of deep hospital clinical data linked with claims to address evidence gaps, the collaboration provides value across the entire drug and medtech lifecycle.

The partnership builds upon the trusted relationship Alira Health has developed with life sciences industries for over 20 years, grounded in clinical knowledge and a strategic mindset, with the participation of patients as drivers. Sancare’s expertise in developing the Realli solution, a platform that provides near real-time access to connected full content EMRs from its partner hospitals linked with claims, shortens time to study results.

About Alira Health

Alira Health is a global advisory and clinical research firm whose mission is to humanize healthcare and life sciences, in partnership with patients, through innovative technologies and expert guidance. From development to medical care, Alira Health complements the expertise of its pharma, biotech, medtech, and patient advocacy clients with a full spectrum of services across their entire solutions lifecycle. Learn more at AliraHealth.com.

About Sancare

Sancare is an award-winning firm whose mission is to harness the potential of hospital data through AI, by specializing in machine learning applied to hospital data, and collaborating with some of the best scientists in the field. The company accelerates clinical research and increases the density of real-world studies through proprietary access to comprehensive hospital EMR and administrative data, powered by proprietary AI and semantic enrichment. Learn more at Sancare.fr.

Related news

Blog February 21, 2024
The Importance of Involving Patients in the Health Technology Assessment Process for Rare Diseases
Experts Annabel de Maria and Ahmad Bechara share how engaging rare disease patients in the HTA process gives them the opportunity to have a meaningful impact.
Healthcare Technology Patient Engagement Rare Disease
News January 11, 2024
Alira Health and Sancare Join Forces to Drive Healthcare Innovation in France
Alira Health, a global advisory and clinical research firm, and Sancare, an award-winning firm whose mission is to harness the potential of hospital data through artificial intelligence(...)
Healthcare Technology Hospitals Research and Development
Events January 9, 2024
AI and How It Will Change Life Sciences Forever
This panel will explore how AI is transforming the field of life sciences, from accelerating research and drug discovery to improving patient care and disease management.
Research and Development
Scientific Articles December 18, 2023
Best Practices for Health Technology Assessment of Robotic Assisted Surgery
An expert panel developed seven best-practice recommendations for evaluating Robotics Assisted Surgical systems and here are the results.
Healthcare Technology HEOR Medical Robotics
News November 21, 2023
Alira Health to Present at the Piper Sandler 35th Annual Healthcare Conference
Alira Health announced that Gabriele Brambilla, Alira Health’s Chief Executive Officer and Co-Founder, and Piergiulio Lauriano, Chief Strategy Officer at Alira Health, will present(...)
Healthcare Technology Life Sciences
Events October 11, 2023
ISPOR Europe
Will we see you at ISPOR Europe 2023? We'll be presenting on topics including Lupus, value-based contracts, HEOR trends and more.
HEOR Research and Development
Publications September 22, 2023
Impact of the New EU HTA Regulation on Access to Innovative Medicines in Europe
In this interview, Alira Health Partner Chus Castillo gives updates on HTA Regulation, related challenges, and potential effect on access to innovative medicines.
Biotech Healthcare Technology Regulatory Spain
Welcome to Alira Health. This site is best viewed in Chrome, Microsoft Edge, or Firefox.